Top news of the week: 14.09.2021.
Healthcare
Sanofi acquires Kadmon for $1.9 billion, adding transplant medicine drug
Once the Kadmon acquisition closes, Rezurock will become the third drug in Sanofi’s established transplant medicine business.
Diaccurate Adds Merck PAM Inhibitor to Oncology/Immunology Pipeline
French biotech Diaccurate bolstered its oncology and immunology pipeline with the acquisition of a Phase II-ready dual PAM inhibitor from Merck KGaA, Darmstadt, Germany.
Return of the mammoth? George Church-backed company launches with $15 million for elephant-sized quest
The funding is likely to force policymakers to engage more directly with what has until now seemed more science fiction than reality.
Global Roundup: ProQR Licenses Axiomer RNA Editing Platform to Eli Lilly
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
Avillion announces positive results in MANDALA and DENALI Phase III trials of AstraZeneca’s PT027, a fixed-dose combination of albuterol and budesonide, demonstrating significant benefits for asthma patients
100% trial success rate across multiple therapy areas continues for Avillion, delivering global pivotal programme of 4 studies with more than 4,000 patients PT027 significantly reduced the ...
08 Public Safety Update_SPIKEVAX_8 September 2021
Updates on safety assessments for Spikevax PRAC assessed new safety data, including the latest Monthly Summary Safety Report (MSSR)2 from the marketing authorisation holder and …